Radon and Lung Cancer: Current Status and Future Prospects

sciencedirect.com/science/articl…

Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFRmutant lung cancer

nature.com/articles/s4200…

IASLC Members We Need Your Opinion! Dr. Narjust Florez, MD, FASCO encourages all of us to help shape the IASLC community by taking our 5-min survey in multiple languages to help us understand diverse needs & enhance initiatives. Let's build inclusivity together! gather.video/h7wo

Not one, not 2, but 3 lung cancer plenaries at #ASCO24 ! Early telemed pall care, the LAURA trial of consolidation osimertinib after CRT for stage 3 EGFR non small cell lung cancer & the ADRIATIC trial of consolidation immunotherapy after CRT for small cell lung cancer! #lcsm

The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from
an Italian knowledge-based database

lungcancerjournal.info/article/S0169-…

🫁 End 🫁

IASLC
EGFR Resisters
Exon 20 Group, a multi-stakeholder organization
METCrusaders
KRASKickers
BrafBombers
ALK Positive
ALKFusion
The ROS1ders, Inc.
RET Renegades
NTRKers
#TNMclassifcation
#lungcancer

Wonderful #LCSM program to be presented at #ASCO24 ! Looking forward to this! LungCancerRx 🫁💊

⏰NOW OUT‼️ #ASCO24 Abstract Titles
🔥Lung Cancer - NSCLC Loco-Regional/SCLC/Other
☑️#8001 BEAT-SC Dr.Yuichiro Ohe
☑️ #LBA8002 BEAT-meso Sanjay Popat
☑️#8005 ADAURA MRD A/Prof Tom John
☑️#8505 ALINA Dr.Nishio Makoto
and others
#LCSM OncoAlert ASCO

Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer

lungcancerjournal.info/article/S0169-…

These findings suggest that upfront LT + Osimertinib can offer improved outcomes

Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment

aacrjournals.org/cancerrescommu…

Krystal Biotech doses first subject in lung cancer drug trial
clinicaltrialsarena.com/news/krystal-t…

'Lung Cancer Cells Switch Oncogenic Drivers'

the-scientist.com/lung-cancer-ce…

Today (April 23) is the last day to get your donation quadrupled so please donate here: fundraise.lungevity.org/index.cfm?fuse… We are so close to our goal. RESEARCH=SURVIVAL! #lcsm

Are people getting denials from insurance for treatment beyond 3 years of osi in metastatic setting (egfr + nsclc) despite sending all the necessary documents? #ascoadvocacy @asco #lcsm
Writing an appeal letter and trying to maintain professionalism

New treatment options for patients with oncogene-addicted NSCLC focusing on EGFR-mutant tumors.

ASCO Educational book 📖 DOI 👉🏻 10.1200/EDBK_432516

#nsclc #egfr #lcsm

Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in #EGFR Mutant 🫁 Lung Cancer
🔸️defactinib/
🔸️saracatinib/
🔸️osimertinib
🔻
doi.org/10.1016/j.jtoc…

Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors

ejcancer.com/article/S0959-…

An engineering strategy to target activated EGFR with CAR T cells

cell.com/cell-reports-m…

Directed-evolution approach to empower EGFR targeting for immunotherapy

cell.com/cell-reports-m…

84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer

sciencedirect.com/science/articl…